Prof. Dr. Turgay Çelikel
OncologyVerified
- 47+years exp.
English · Turkish
FromPrice on request
Free quote
60 seconds · no obligationView Profile
Radiotherapy & Radiosurgery
Radioembolization for liver cancer
Radioembolization for liver cancer, also known as selective internal radiation therapy (SIRT) or TARE, delivers radioactive microspheres directly to hepatic tumours via the hepatic artery. This guide details the two-stage mapping and treatment process, clinical eligibility, expected outcomes, approximate international costs across Turkey, the UK, US, and Germany, recovery steps, potential complications, and essential standards for choosing a specialised oncology hospital.
A written plan with the surgeon's name and the full price — usually within 24 hours.
- Category
- Radiotherapy & Radiosurgery
- Hospitals
- 2
- Verified
- 1
- Price from
- Price on request
Verified surgeons for Radioembolization for Liver Cancer
1 doctor Compare doctors, ratings and prices — ask any of them for a free quote.
What is radioembolization for liver cancer and how does it target tumours?
Radioembolization for liver cancer, also referred to as selective internal radiation therapy (SIRT) or transarterial radioembolization (TARE), is a catheter-based treatment designed for primary hepatic malignancies and metastatic liver disease. The liver has a unique vascular anatomy: healthy liver tissue receives roughly 75% of its blood from the portal vein, whereas malignant liver tumours draw 80% to 90% of their nourishment from hepatic arterial branches. By placing a microcatheter into these tumour-feeding vessels, an interventional radiologist delivers microscopic radioactive beads directly into the cancer.
These microspheres, loaded with yttrium-90 (Y-90) or holmium-166, lodge in the tumour microvasculature. The beta radiation travels only 2.5 to 11 mm into tissue, delivering high-dose local radiation while sparing normal liver parenchyma. It treats unresectable hepatocellular carcinoma (HCC), cholangiocarcinoma, and liver metastases from colorectal or neuroendocrine cancers. See our guide to oncology treatments in Turkey.
How does radioembolization work: the two-stage mapping and infusion process
Radioembolization is a coordinated two-stage procedure that prioritises patient safety and anatomical precision.
Stage one is the diagnostic mapping angiogram, carried out one to two weeks before treatment. Under local anaesthesia and light conscious sedation, an interventional radiologist introduces a microcatheter into the femoral or radial artery and navigates into the hepatic arterial tree. Small accessory vessels branching to the stomach or bowel are closed with tiny coils to prevent non-target radiation. A test tracer, technetium-99m macroaggregated albumin (Tc-99m MAA), is infused, followed by a SPECT-CT scan to calculate the lung shunt fraction, ensuring the lungs will not receive unsafe radiation.
Stage two is the therapeutic infusion. Once the custom isotope is prepared, the microcatheter is repositioned into the targeted liver arteries, and the radioactive microspheres are slowly infused over twenty to thirty minutes. The entire catheter procedure takes sixty to ninety minutes, and the patient is monitored in hospital before discharge.
Does radioembolization for liver cancer work? Clinical evidence and tumour control
Clinical guidelines from ESMO and NCCN confirm that radioembolization is an established local therapy for selected liver tumours. It achieves local disease control through tumour necrosis, vascular shutdown, and reduction in tumour volume.
In clinical practice, radioembolization serves three roles. As a palliative option, it halts tumour growth and extends progression-free survival in patients who cannot undergo surgery or standard chemoembolization. As a bridge to transplant, it stabilises tumours while patients wait for a donor liver. In select solitary tumours, high-dose radiation segmentectomy can shrink the lesion and stimulate the healthy liver lobe to grow, sometimes making surgical resection possible.
Radioembolization is a loco-regional treatment; it does not treat cancer outside the liver. For extrahepatic tumours, external beam therapies like tomotherapy or gamma knife stereotactic radiosurgery may be evaluated alongside systemic therapy.
Radioembolization for liver cancer cost in Turkey, the UK, US, and Germany
The radioembolization for liver cancer cost reflects the technical expertise required and the expense of custom-ordered isotopes. Y-90 microspheres are manufactured individually per patient and decay quickly, requiring prompt delivery. The table shows approximate international price ranges.
| Country | Approximate cost range |
|---|---|
| Turkey | €12,000 – €25,000 |
| United Kingdom | €25,000 – €45,000 |
| United States | €40,000 – €90,000 |
| Germany | €22,000 – €42,000 |
The radioembolization for liver cancer price depends on whether one or both lobes are treated, whether vessel coiling is needed during mapping, and hospital stay length. An all-inclusive package in Turkey typically covers consultations, blood tests, mapping angiography, the Tc-99m scan, the Y-90 isotope, catheterisation fees, one to two nights in hospital, medications, and airport transfers.
Radioembolization (SIRT) vs TACE and stereotactic radiotherapy
Patients often compare radioembolization with transarterial chemoembolization (TACE) and stereotactic body radiation therapy (SBRT). Each option addresses different clinical circumstances.
| Method | Best suited to | Typical limits |
|---|---|---|
| Radioembolization (SIRT / TARE) | Intermediate or advanced unresectable liver tumours; patients with branch portal vein thrombosis | Requires preserved liver function; does not treat extrahepatic spread; requires two hospital procedures |
| Chemoembolization (TACE) | Localised hepatocellular carcinoma confined to the liver with a fully open portal vein | Higher risk of liver ischemia; unsuited to major portal vein occlusion |
| Stereotactic Radiotherapy (SBRT) | Small, well-defined solitary or oligometastatic liver lesions away from bowel loops | Limited by respiratory liver movement and cumulative radiation tolerance of adjacent tissues |
A key difference is that radioembolization microspheres do not completely block blood vessels. Patients with partial portal vein thrombosis can often undergo radioembolization safely, whereas TACE in those cases carries serious risks of liver damage.
Who is a good candidate for radioembolization, and who is not?
Candidate selection by a multidisciplinary team is essential for treatment safety and effectiveness. Suitable candidates typically meet these criteria:
- Confirmed primary liver cancer (HCC, cholangiocarcinoma) or liver-dominant metastases from colorectal or neuroendocrine tumours.
- Preserved liver function, classified as Child-Pugh class A or early, well-compensated class B (bilirubin under 2.0 mg/dL).
- Good performance status, corresponding to ECOG 0, 1, or selected 2.
- Main portal vein trunk open, even if branch vessels are involved.
- Acceptable lung shunt fraction (below 20% on the MAA scan) with no uncorrectable gastrointestinal collateral flow.
Patients are unsuited if they have decompensated cirrhosis with ascites, jaundice, or encephalopathy (Child-Pugh C), extensive extrahepatic metastases, severe kidney failure, or lung shunting that exceeds safe radiation thresholds.
What to expect from imaging results after radioembolization
Assessing treatment results after radioembolization requires specific imaging criteria. A treated liver tumour rarely shrinks immediately on standard CT scans; initial scans at four to six weeks may even show slight swelling due to local tissue inflammation.
Interventional radiologists evaluate response using modified Response Evaluation Criteria in Solid Tumors (mRECIST) or contrast-enhanced MRI. Under mRECIST, radiologists look for the loss of arterial blood flow within the tumour rather than size change alone. A positive response appears as internal tumour necrosis, indicating cancer cell death even if the structural lesion remains. PET-CT scans at twelve weeks typically show a marked drop in metabolic activity.
Radioembolization for liver cancer recovery and trip timeline in Turkey
The radioembolization for liver cancer recovery period involves minimal wound care because access is through a tiny wrist or groin puncture with no surgical incisions.
For radioembolization for liver cancer in Turkey, international patients usually stay ten to fourteen days if mapping and treatment happen in one trip. Alternatively, patients can visit for three days for mapping, return home while the Y-90 isotope is prepared, and return for a four-day infusion visit. After treatment, patients remain in hospital for twenty-four to forty-eight hours for observation.
Specialised centres providing radioembolization for liver cancer Turkey manage post-embolization symptoms closely. During the first week, over half of patients notice mild fatigue, low fever, nausea, or abdominal ache. Prescribed medication controls these effects well. Most patients resume normal daily routines within two to three weeks and can fly home three to four days after the infusion.
Risks, side effects, and safety considerations
Radioembolization has a favourable safety record when performed in regulated facilities. Professional standards from CIRSE and the SIR underline the importance of the mapping stage to prevent complications.
Potential side effects and complications include:
- Post-embolization syndrome: Temporary fatigue, mild fever, nausea, and right-sided abdominal tightness during the first week.
- Liver enzyme changes: Temporary rises in liver enzymes that usually settle within four to six weeks.
- Non-target embolization: Unintended microsphere flow into stomach or intestinal vessels, causing ulcers or inflammation; the mapping scan is designed to prevent this.
- Radiation-induced liver disease: A rare complication seen in fewer than 4% of patients with advanced cirrhosis, causing fluid retention and jaundice.
- Radiation pneumonitis: Lung inflammation from excessive shunting, prevented by strict pre-treatment MAA testing.
How to choose a specialised hospital in Turkey and red flags to watch for
Radioembolization requires close cooperation between interventional radiology, medical oncology, and nuclear medicine. Choose a licensed hospital with an active multidisciplinary tumour board, modern angiography suites, and on-site SPECT-CT and PET-CT imaging.
Red flags include clinics that skip the mapping angiogram, promise a guaranteed cure or complete tumour eradication, offer treatment to patients with decompensated Child-Pugh C cirrhosis, or give fixed quotes without reviewing recent MRI scans and liver blood tests. Learn how our process works and request an assessment through our free quote page.
Essential questions to ask your interventional oncology team
Consider asking your medical team these specific questions before starting treatment:
- Is radioembolization planned for local control, symptom relief, or downstaging toward surgery?
- Which microsphere type (resin or glass) suits my tumour type and anatomy?
- What did my mapping angiogram show regarding lung shunt percentage and vessel anatomy?
- Will treatment cover one lobe or both lobes sequentially?
- What medications will I receive to manage post-treatment fatigue and nausea?
- How will follow-up scans be reviewed with my oncologist at home?
Conditions treated with Radioembolization for Liver Cancer
Hospitals with Oncology in Turkey
Frequently asked questions
Radioembolization for liver cancer, also known as selective internal radiation therapy (SIRT) or transarterial radioembolization (TARE), is a minimally invasive treatment that delivers radioactive micro-beads directly into the liver tumours via the hepatic artery, targeting cancer cells with high-dose local radiation while sparing most normal liver tissue.
Clinical trials and international oncology guidelines show that radioembolization can halt tumour progression, reduce tumour burden, and in some cases downstage inoperable tumours so they become suitable for surgical resection or liver transplantation. However, it is a local hepatic treatment rather than a curative therapy for systemic cancer spread.
The approximate radioembolization for liver cancer cost in Turkey ranges between €12,000 and €25,000 per treated lobe, compared with €25,000 to €45,000 in the UK. The exact price depends on whether unilateral or bilobar treatment is required, pre-treatment mapping scans, nuclear isotope supply, and hospital stay duration.
Post-treatment imaging, usually performed via contrast-enhanced MRI or multiphase CT after six to twelve weeks, evaluates treatment response. Successful therapy typically shows internal tumour necrosis, reduced blood flow, and shrinkage on modified RECIST criteria, rather than immediate disappearance of the mass on standard scans.
Most patients experience post-embolization syndrome, characterised by mild fatigue, low-grade fever, nausea, and abdominal discomfort lasting three to seven days. Prescription medication manages these symptoms effectively. Patients typically leave hospital within 24 to 48 hours and resume light everyday activities within a week.
The catheter procedure is performed under local anaesthesia with conscious sedation, so patients feel minimal discomfort during the infusion. Mild to moderate abdominal aching or cramping can occur as the microspheres lodge in the tumour vessels, which medical teams control with anti-inflammatory and pain-relieving medication.
The radioactive microspheres emit therapeutic beta radiation over approximately ten to fourteen days, after which the isotope decays into harmless elemental material. The biological effects on tumour cells, including cellular death and vascular closure, continue to develop over several months following treatment.
Primary risks include post-embolization syndrome, temporary elevation of liver enzymes, radiation-induced liver disease (RILD), and unintentional non-target embolization causing stomach or duodenal ulcers. A mandatory pre-treatment mapping angiogram with a test isotope significantly minimises non-target radiation risks.
Both procedures use microcatheters placed in the hepatic artery. TACE delivers concentrated chemotherapy agents combined with blood vessel blocking particles to starve tumours of blood. Radioembolization delivers microscopic radioactive beads that destroy tumour cells primarily through localised radiation, causing less severe vessel occlusion and fewer ischemic symptoms.
Patients usually require ten to fourteen days in Turkey if both the diagnostic mapping angiogram and the therapeutic radioembolization infusion are completed in a single trip. Alternatively, some patients travel twice for three to four days each, separated by a one to two week planning interval.
Patient stories